FR3074681B1 - Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes - Google Patents

Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Download PDF

Info

Publication number
FR3074681B1
FR3074681B1 FR1761807A FR1761807A FR3074681B1 FR 3074681 B1 FR3074681 B1 FR 3074681B1 FR 1761807 A FR1761807 A FR 1761807A FR 1761807 A FR1761807 A FR 1761807A FR 3074681 B1 FR3074681 B1 FR 3074681B1
Authority
FR
France
Prior art keywords
basal insulin
polyaminoacid
carboxylates
carrying
injection solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1761807A
Other languages
English (en)
Other versions
FR3074681A1 (fr
Inventor
You-Ping Chan
Alexandre GEISSLER
Romain Noel
Richard Charvet
Nicolas LAURENT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to FR1761807A priority Critical patent/FR3074681B1/fr
Priority to CN201880088662.5A priority patent/CN111698999A/zh
Priority to PCT/EP2018/083558 priority patent/WO2019110625A1/fr
Priority to EP18812169.3A priority patent/EP3720472A1/fr
Priority to US16/770,787 priority patent/US20220040099A1/en
Priority to MA051597A priority patent/MA51597A/fr
Priority to SG11202005322RA priority patent/SG11202005322RA/en
Priority to CN201880088456.4A priority patent/CN111727049A/zh
Priority to KR1020207019244A priority patent/KR20200106891A/ko
Priority to BR112020011570-3A priority patent/BR112020011570A2/pt
Priority to PCT/EP2018/083896 priority patent/WO2019110773A1/fr
Priority to TW107144180A priority patent/TWI813604B/zh
Priority to CA3084688A priority patent/CA3084688A1/fr
Priority to US16/213,809 priority patent/US20190216931A1/en
Priority to EP18814899.3A priority patent/EP3740229A1/fr
Priority to JP2020531052A priority patent/JP2021505607A/ja
Priority to MX2020005913A priority patent/MX2020005913A/es
Publication of FR3074681A1 publication Critical patent/FR3074681A1/fr
Priority to US16/563,027 priority patent/US20190388515A1/en
Application granted granted Critical
Publication of FR3074681B1 publication Critical patent/FR3074681B1/fr
Priority to PH12020550827A priority patent/PH12020550827A1/en
Priority to IL275192A priority patent/IL275192A/en
Priority to US16/902,176 priority patent/US11883496B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

L'invention concerne des compositions stables physiquement sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,0 et 8,0, comprenant au moins : a) une insuline basale dont le point isoélectrique (pI) est compris entre 5,8 et 8,5 et b) un co-polyaminoacide porteur de charges carboxylates et d'au moins un radical hydrophobe.
FR1761807A 2017-12-06 2017-12-07 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Active FR3074681B1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FR1761807A FR3074681B1 (fr) 2017-12-07 2017-12-07 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
PCT/EP2018/083558 WO2019110625A1 (fr) 2017-12-06 2018-12-04 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
EP18812169.3A EP3720472A1 (fr) 2017-12-06 2018-12-04 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US16/770,787 US20220040099A1 (en) 2017-12-06 2018-12-04 Injectable solution at ph 7 comprising at least a basal insulin which pi is comprised between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
CN201880088662.5A CN111698999A (zh) 2017-12-06 2018-12-04 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph为7的可注射溶液
TW107144180A TWI813604B (zh) 2017-12-07 2018-12-07 包含至少一具有pi從5.8至8.5之基礎胰島素以及一帶有羧酸鹽電荷及疏水基之共聚胺基酸的可注射ph7溶液
CN201880088456.4A CN111727049A (zh) 2017-12-07 2018-12-07 Ph 7的包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的可注射溶液
KR1020207019244A KR20200106891A (ko) 2017-12-07 2018-12-07 pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
BR112020011570-3A BR112020011570A2 (pt) 2017-12-07 2018-12-07 Solução injetável a um ph 7 compreendendo pelo menos uma insulina basal apresentando um pi entre 5,8 e 8,5 e um co-poliaminoácido contendo cargas de carboxilato e radicais hidrofóbicos
PCT/EP2018/083896 WO2019110773A1 (fr) 2017-12-07 2018-12-07 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
MA051597A MA51597A (fr) 2017-12-07 2018-12-07 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
SG11202005322RA SG11202005322RA (en) 2017-12-07 2018-12-07 Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
US16/213,809 US20190216931A1 (en) 2017-12-07 2018-12-07 Injectable ph 7 solution comprising at least one basal insulin having a pi from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP18814899.3A EP3740229A1 (fr) 2017-12-07 2018-12-07 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
JP2020531052A JP2021505607A (ja) 2017-12-07 2018-12-07 ５．８〜８．５のｐＩを有する少なくとも１つの基礎インスリンならびにカルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むｐＨ７の注射溶液
MX2020005913A MX2020005913A (es) 2017-12-07 2018-12-07 Solución inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoácido con cargas de carboxilato y radicales hidrofóbicos.
CA3084688A CA3084688A1 (fr) 2017-12-07 2018-12-07 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US16/563,027 US20190388515A1 (en) 2017-12-07 2019-09-06 Injectable solution at ph 7 comprising at least one basal insulin the pi of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
PH12020550827A PH12020550827A1 (en) 2017-12-07 2020-06-04 Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
IL275192A IL275192A (en) 2017-12-07 2020-06-07 Solution for injection at pH 7 containing at least one basic insulin with a PI of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
US16/902,176 US11883496B2 (en) 2017-12-07 2020-06-15 Injectable pH 7 solution comprising at least one basal insulin having a pI from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1761807 2017-12-07
FR1761807A FR3074681B1 (fr) 2017-12-07 2017-12-07 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes

Publications (2)

Publication Number Publication Date
FR3074681A1 FR3074681A1 (fr) 2019-06-14
FR3074681B1 true FR3074681B1 (fr) 2020-01-03

Family

ID=62143250

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1761807A Active FR3074681B1 (fr) 2017-12-06 2017-12-07 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes

Country Status (1)

Country Link
FR (1) FR3074681B1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2985428B1 (fr) * 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
CN104114155B (zh) * 2012-01-09 2019-02-15 阿道恰公司 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液

Also Published As

Publication number Publication date
FR3074681A1 (fr) 2019-06-14

Similar Documents

Publication Publication Date Title
PH12018502558A1 (en) Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
PH12020550827A1 (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
FR3001896B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
FR3001895B1 (fr) Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
MX2018015070A (es) Composiciones en forma de solucion acuosa inyectable, que comprende glucagon humano y un co-poliaminoacido injertado en el extremo.
WO2019110797A8 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MA51127A (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
EA201791467A1 (ru) Водный офтальмологический раствор
EA201790997A1 (ru) Композиции гликопептидов
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
GEP20207139B (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
PH12020550828A1 (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
MA51597A (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3074681B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3084584B1 (fr) Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR3074422B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3043557B1 (fr) Composition a action rapide d'insuline comprenant un citrate substitue
FR3061023B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3074683B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3074680B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083085B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3074682B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3061660B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3079414B1 (fr) Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20190614

PLFP Fee payment

Year of fee payment: 3

GC Lien (pledge) constituted

Effective date: 20191024

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

RG Lien (pledge) cancelled

Effective date: 20231011

PLFP Fee payment

Year of fee payment: 7